Ligand Pharmaceuticals Inc.'s cancer drug Targretin missed its primary endpoints in two pivotal trials evaluating the drug in front-line combination therapy to treat non-small-cell lung cancer. (BioWorld Today)
Ligand Pharmaceuticals Inc.'s cancer drug Targretin missed its primary endpoints in two pivotal trials evaluating the drug in front-line combination therapy to treat non-small-cell lung cancer. (BioWorld Today)
Expecting an increase in research and development costs this year, Cardiome Pharma Corp. is raising $51 million in a public offering to continue its clinical programs for atrial fibrillation and congestive heart failure. (BioWorld Today)
Expecting an increase in research and development costs this year, Cardiome Pharma Corp. is raising $51 million in a public offering to continue its clinical programs for atrial fibrillation and congestive heart failure. (BioWorld Today)
